QNT Stock Quantinuum Inc.

$27.74
1d-0.79%5d-21.64%1m-28.23%
At close · Nov 20, 4:00 PM ET
After hours $28.35 +2.2% · Nov 20, 7:56 PM ET
52w low $27.111% of range$86.79 52w high
Price

Today’s call · QNT

All live ideas →

4 of 4 technical checks lean bearish

QNT has a mixed trend, momentum soft. $30 is the level overhead; $25 the first support below.

No open idea.From $27.74 the reward-to-risk to $30 against $25 is 0.8 — below the 3:1 bar.
What would create one:
  • A close above $30 or below $25 on rising volume — a way out of the range.
Alert me at a level

The brief

Price vs 50-day · belowMACD · bearishRSI momentum · 365-day tape · -21.6%
volumeVolume is expanding vs its 20-day average.
newsQuantinuum Inc. — Quarterly report (10-Q)
All readings
TrendRange / mixed · below 50-day
MomentumRSI 35.8 · MACD bearish
Trend strengthADX 17.5 · weak or range
Location-31.6% vs 50-day MA
52-week range-67% from high · +0% from low
VolatilityATR 3.83 · ~13.8%/day
RSI 14
35.8
MACD
-2.65
ADX 14
17.5
ATR 14
3.83
SMA 50
$40.56
SMA 200
—

Levels that matter

$30round+8.2%
$35round+26.2%
$40.56sma 50+46.2%
$25round−9.9%
$20round−27.9%

Compare with…

Analyst overview · Nov 16

Quantinuum (QNT) under pressure, downside bias persists

Quantinuum Inc. posted a spectacular 233% year‑over‑year revenue jump in its third‑quarter filing, yet the stock slid to $33.65, a 21.7% drop from the $43 peak reached six days earlier. The balance of evidence points to a bearish outlook for the next two to six weeks, with the daily trend echoing a weekly downtrend and the price sitting well below its 40‑week average. A break below the round $30 level would confirm the downside case, while the upside target at the 52‑week low of $29.82 offers limited upside and fails to meet a 3‑to‑1 reward‑to‑risk ratio.

Why it matters

The recent 10‑Q revealed revenue of $9.1 million, up from $2.9 million a year earlier, but also a net loss of $17 million. The market absorbed the top‑line growth without a rally; instead, the stock fell sharply, suggesting that investors had already priced in the earnings beat and were more concerned about the widening loss and cash burn. The move was not driven by sector dynamics alone: the technology‑focused XLK ETF fell 2.63% over the past five days, while the broader S&P 500 slipped only 0.45%.

When the stock’s 5‑day performance is compared to its peers, the picture is stark. QNT declined 15.96% versus a 2.63% drop in XLK and a modest 0.45% dip in the S&P 500, leaving the stock lagging the market by 13.3 percentage points. This out‑performance of the downside indicates that the sell‑off was driven primarily by stock‑specific factors rather than a sector‑wide rotation.

The debate surrounding QNT centers on two opposing views. One camp argues that the revenue surge signals a turning point for the quantum‑computing business, pointing to the 233% growth as a catalyst for future profitability. The other camp counters that the loss magnitude and the stock’s position below its 40‑week average underscore a structural weakness, noting that the price is already 12.84% above the 52‑week low and that volume is down 78.4% versus the 20‑day average, indicating weak buying interest. Both arguments are documented in the SEC filing and the market data, but the evidence leans toward the downside narrative.

Analyst coverage remains overwhelmingly optimistic, with a consensus of strong‑buy and a mean price target of $71.15, roughly 52.7% above the current price. However, the consensus does not reflect the immediate market reality; the stock’s price is far below even the low end of the target range ($50), highlighting a disconnect between long‑term expectations and short‑term price action.

What the evidence says

On the long‑term horizon, the weekly trend remains down, and the price sits below its 40‑week average, keeping the bearish thesis intact. The 52‑week range shows the stock trading 59.54% below its high of $83.17 and only 12.84% above its low of $29.82, reinforcing a prolonged weakness.

For the next two to six weeks, the balance of evidence is negative with high conviction. The assessment notes that the daily trend aligns with the weekly downtrend, the stock is lagging the S&P 500 by 18.5% over 50 days, and it trails XLK by 10.9% over the same period. These three points satisfy three of four conviction criteria, justifying a high‑conviction bearish stance. The strongest counter‑argument would be a rapid rebound in volume or a surprise positive earnings surprise, but the current volume is down 78.4% and the earnings report already showed a widening loss, making that scenario unlikely.

Levels that matter

The structure holds below the round $35 level, a zone where sellers have repeatedly stepped in on rallies. The weekly trend would only be considered ended if the price closes above the 50‑day SMA at $42.13, a level that also serves as a resistance point.

The breakout math sets the downside trigger at a daily close below the round $30 level. The stop is placed at $35.91, derived from $35 plus a quarter of the 14‑day ATR ($3.65). The only target is the 52‑week low of $29.82, which yields a reward‑to‑risk ratio of zero because the stop sits above the target. The math does not achieve a 3‑to‑1 ratio; a price move to roughly $26 would be required to meet that threshold, which is well below the current support at $29.82.

What would change the picture

A weekly close above the 50‑day SMA at $42.13 would alter the narrative, indicating that the weekly downtrend has been broken. Additionally, any unexpected positive earnings revision or a significant uptick in volume could shift sentiment, but those are non‑price factors.

What to watch

  • Next earnings release on November 5, 2026 – the key number will be the net loss figure and cash‑burn guidance.
  • Sector moves: a rally in XLK or a broader tech bounce could provide temporary support.
  • Valuation: the consensus price target of $71.15 remains more than 50% above the current price, highlighting a large gap between analyst optimism and market pricing.

MarketCrew is AI-powered and can make mistakes — double-check before acting. Informational only, not investment advice.